Back to research

Research paper

Pediatric autoimmune encephalitis (clinical spectrum, first-line IVMP + oral taper, and follow-up outcomes)

Framework paper on pediatric autoimmune encephalitis plus adjacent Indian NMDAR case series (n=21). Standard first-line therapy is IV methylprednisolone 30 mg/kg/day x 3-5 days followed by oral taper at 1-2 mg/kg/day for ~12 weeks. In the Indian NMDAR series, 61.9% of children required psychotropic medication for behavioral symptoms (predominantly atypical antipsychotics - quetiapine, risperidone, olanzapine). Mean time to significant clinical behavioral response 7.4 +/- 4.8 months (range 2-19). Residual irritability and anger outbursts persisted at last follow-up in 4/21 children (3 of whom were prepubertal).

Indexed context

Nosadini M, Mohammad SS, et al.

autoimmune-encephalitisnmdarpediatricmethylprednisolonepulseoral-taperbehavioraggressionirritabilitylong-term-outcome

Markdown path

content/research/papers/2019-nosadini-pediatric-autoimmune-encephalitis-outcomes.md

Findings

Framework paper on pediatric autoimmune encephalitis plus adjacent Indian NMDAR case series (n=21). Standard first-line therapy is IV methylprednisolone 30 mg/kg/day x 3-5 days followed by oral taper at 1-2 mg/kg/day for ~12 weeks. In the Indian NMDAR series, 61.9% of children required psychotropic medication for behavioral symptoms (predominantly atypical antipsychotics - quetiapine, risperidone, olanzapine). Mean time to significant clinical behavioral response 7.4 +/- 4.8 months (range 2-19). Residual irritability and anger outbursts persisted at last follow-up in 4/21 children (3 of whom were prepubertal).

Why it may matter for Levi

Closest pediatric IVMP regimen match available in the indexed literature, but still differs from Levi's pulse-only course because it tails into a long oral taper. Confirms that in pediatric neuroinflammatory cohorts on pulse + taper regimens, ongoing behavioral difficulties in the 1-month-plus post-pulse window are common (~62% require psychotropics) and can persist for months. Cannot separate true pulse-aftermath from residual underlying disease. Does not resolve the specific 3-week-post-pulse question but confirms that pediatric neuroinflammatory patients frequently have behavioral difficulties in the 1-month-plus window.

Paper text

Pediatric autoimmune encephalitis — IVMP-plus-taper regimen and behavioral outcomes

Source

Regimen — important distinction from Levi's pulse

  • Standard pediatric AE first-line is IV methylprednisolone 30 mg/kg/day × 3–5 days followed by an oral steroid taper at 1–2 mg/kg/day for ~12 weeks.
  • Levi received only the 3-day IV pulse with no oral taper.
  • So in AE the 1-month post-pulse window is actually a still-on-steroid window (low-dose oral), not a true washout. That limits how directly the AE behavioral follow-up data map onto Levi.

Behavioral findings at follow-up

  • In the Indian pediatric NMDAR series (n=21), 61.9% required psychotropic medication for behavioral symptoms during and after immunotherapy, most commonly atypical antipsychotics (quetiapine, risperidone, olanzapine).
  • Mean time to significant clinical (behavioral) response: 7.4 ± 4.8 months, range 2–19 months.
  • In 4/21 children, residual irritability and anger outbursts persisted at last follow-up (mean 17.3 months). 3 of these 4 were prepubertal.
  • Follow-up outcome summary: behavioral improvement observed in all children by final follow-up, but clinically meaningful irritability can persist for months or longer.

Limitations as a direct analogue for Levi

  • In AE the underlying disease is causing the behavioral symptoms — so residual irritability at follow-up is not separable from the pulse-steroid effect itself.
  • The oral taper after the IV pulse makes the AE cohort's exposure profile structurally different from Levi's (pulse-only, no taper).
  • Despite the overlap in IVMP regimen timing and pediatric age bracket, AE is not a clean control for Levi's single-pulse DEE-SWAS exposure.

Levi-relevant takeaways

  • Reinforces that in pediatric IVMP-treated neuroinflammatory cohorts, irritability, anger outbursts, and aggression are common enough to require psychotropics in the majority (~62%) during and after treatment. Does not tell us what fraction of that is steroid rebound vs. residual disease.
  • Documents that when behavioral symptoms persist, they can persist for months, not just weeks.
  • Does not resolve the specific 3-week-post-pulse question, but confirms that pediatric neuroinflammatory patients on pulse + taper frequently have ongoing behavior difficulties in the 1-month-plus window.